Protara Therapeutics

Protara Therapeutics

TARA· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +0.9% in FY2025

Jesse Shefferman is the CEO of Protara Therapeutics and was paid $2.7M in FY2025 (Dec), up 48%.

Pay$100 in the stock at the end of FY21 → $79
CEO pay is from each Protara Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Jesse SheffermanFY2025
  2. 2Leonardo Nicacio, M.D.FY2025
  3. 3Jacqueline Zummo, Ph.D.FY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Protara Therapeutics paid its 3 named executives $5.4M in total in FY2025 (Dec). CEO Jesse Shefferman was paid $2.7M of that.

Name
Jesse SheffermanPresident, Chief Executive Officer and Director
Leonardo Nicacio, M.D.Chief Medical OfficerNot disclosedNot disclosed
Jacqueline Zummo, Ph.D.Chief R&D Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for Protara Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Board2

See all
  • Gregory SargenDirector · 5 yr on the boardIndependentAudit (Chair)—Paid as an executive
  • Jane Huang, M.D.Director · 4 yr on the boardIndependent—Paid as an executive

The board of the latest proxy (FY2025).

Activity

Filings6

See all
Proxy statementDEF 14AApr 28, 2026FY2025
Annual report10-KMar 10, 2026FY2025
Proxy statementDEF 14AApr 25, 2025FY2024
Annual report10-KMar 5, 2025FY2024
Proxy statementDEF 14AApr 26, 2024FY2023
Annual report10-KMar 13, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data